Stock Data
$0.41 (1.77%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Nurix Therapeutics Inc is a biopharmaceutical company in the clinical stage, dedicated to creating innovative treatments for cancer, inflammatory conditions, and other diseases. It focuses on developing small molecule and cell therapies, including a range of drugs aimed at combating B-cell malignancies and autoimmune diseases, as well as advancing immuno-oncology treatments. With strategic collaborations with industry giants like Gilead Sciences, Sanofi S.A., and Seagen Inc., Nurix is at the forefront of leveraging scientific breakthroughs to improve patient outcomes. Founded in 2009 and based in San Francisco, California, Nurix is committed to transforming the therapeutic landscape.
Nurix missed earnings and revenue badly, but the $700 million Roche upfront arriving next quarter will vault cash to $1.14 billion and fund the leap into Phase 3 trials for lead BTK degrader bexobrutideg. The quarterly flop fades against a transformative collaboration that validates targeted protein degradation as the field's future.
1 Article
Our top personal finance-related articles today. Your wallet will thank you later.
